Abstract
Background: Cerebrospinal fluid (CSF) contains pro-growth factors that can affect proliferation, migration and differentiation of Mesenchymal Stem Cells (MSCs).
Objective: This study aimed to isolate MSC like cells from CSF of patients with meningioma and psudotumorcerebri (PTC) and identify differentially expressed proteins in these cells.
Methods: Five patients with newly diagnosed intracranial meningioma and five patients with PTC were recruited in this comparative proteomics study. MSCs were isolated from CSF and validated by mesenchyml and non-mesenchyml fluorochrome antibodies, and flow cytometer analysis. Two- Dimensional Gel Electrophoresis (2-DE) coupled with Mass Spectrometry (MS) was performed to identify differentially expressed proteins.
Results: Microscopic views of the isolated cells as well as flow cytometer analysis were found to be compatible with MSC-like cells. Eight distinct protein spots were differentially and reproducibly expressed among the stained gels of two studied groups. The identified proteins were Phosphoglycerate Mutase 1 (PGAM1), LIM and SH3 domain protein (LASP1), peroxiredoxin-6 (PRDX-6), type I cytoskeletal 9 (KRT9), Superoxide Dismutase (SOD), endoplasmin, Stathmin 1 (STMN1), and glutathione S-transferase (GST).
Conclusion: This study provides new insights into the plausible role of CSF derived MSCs in cancer progression, and reveals a promising therapeutic opportunity for targeting of MSC proteins in patients with meningioma.
Keywords: Meningioma, psudotumorcerebri, cerebrospinal fluid, mesenchymal stem cells, proteomics, staining buffer.
Graphical Abstract
[1]
Hossain, A.; Gumin, J.; Gao, F.; Figueroa, J.; Shinojima, N.; Takezaki, T.; Priebe, W.; Villarreal, D.; Kang, S.G.; Joyce, C.; Sulman, E.; Wang, Q.; Marini, F.C.; Andreeff, M.; Colman, H.; Lang, F.F. Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. Stem Cells, 2015, 33(8), 2400-2415.
[2]
Kang, S.G.; Shinojima, N.; Hossain, A.; Gumin, J.; Yong, R.L.; Colman, H.; Marini, F.; Andreeff, M.; Lang, F.F. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery, 2010, 67(3), 711-720.
[3]
Lim, H.Y.; Kim, K.M.; Kim, B.K.; Shim, J.K.; Lee, J.H.; Huh, Y.M.; Kim, S.H.; Kim, E.H.; Park, E.K.; Shim, K.W.; Chang, J.H.; Kim, D.S.; Kim, S.H.; Hong, Y.K.; Lee, S.J.; Kang, S.G. Isolation of mesenchymal stem-like cells in meningioma specimens. Int. J. Oncol., 2013, 43(4), 1260-1268.
[4]
Kim, J.H.; Lee, S.K.; Yoo, Y.C.; Park, N.H.; Park, D.B.; Yoo, J.S.; An, H.J.; Park, Y.M.; Cho, K.G. Proteome analysis of human cerebrospinal fluid as a diagnostic biomarker in patients with meningioma. Med. Sci. Monit., 2012, 18(11), BR450-BR460.
[5]
Ren, C.; Yin, P.; Ren, N.; Wang, Z.; Wang, J.; Zhang, C.; Ge, W.; Geng, D.; Wang, X. Cerebrospinal fluid-stem cell interactions may pave the path for cell-based therapy in neurological diseases. Stem Cell Res. Ther., 2018, 9(1), 66.
[6]
Majumdar, K.; Mandal, S.; Thakkar, R.; Saran, R.K.; Srivastava, A.K. Meningeal osteochondroma simulating meningioma with metaplastic change: A rare golf-ball-like lesion of non-meningothelial mesenchymal origin. Brain Tumor Pathol., 2014, 31(1), 62-67.
[7]
Ghaderi, A.; Abtahi, S. Mesenchymal stem cells: Miraculous healers or dormant killers? Stem Cell Rev., 2018, 14(5), 722-733.
[8]
Okamoto, H.; Li, J.; Vortmeyer, A.O.; Jaffe, H.; Lee, Y.S.; Glasker, S.; Sohn, T.S.; Zeng, W.; Ikejiri, B.; Proescholdt, M.A.; Mayer, C.; Weil, R.J.; Oldfield, E.H.; Zhuang, Z. Comparative proteomic profiles of meningioma subtypes. Cancer Res., 2006, 66(20), 10199-10204.
[9]
Hammond, J.B.; Kruger, N.J. The bradford method for protein quantitation. Methods Mol. Biol., 1988, 3, 25-32.
[10]
Pandamooz, S.; Naji, M.; Alinezhad, F.; Zarghami, A.; Pourghasem, M. The influence of cerebrospinal fluid on epidermal neural crest stem cells may pave the path for cell-based therapy. Stem Cell Res. Ther., 2013, 4(4), 84.
[11]
Durvasula, S.; Imitola, J. The cerebrospinal fluid-stem cell interactions as target for regenerative therapy in neurological diseases. Stem Cells Dev., 2015, 24(2), 145-146.
[12]
Zhu, M.; Feng, Y.; Dangelmajer, S.; Guerrero-Cazares, H.; Chaichana, K.L.; Smith, C.L.; Levchenko, A.; Lei, T.; Quinones-Hinojosa, A. Human cerebrospinal fluid regulates proliferation and migration of stem cells through insulin-like growth factor-1. Stem Cells Dev., 2015, 24(2), 160-171.
[13]
Xu, L.; Li, G. Circulating mesenchymal stem cells and their clinical implications. J. Orthop. Translat., 2014, 2(1), 1-7.
[14]
Shahar, T.; Rozovski, U.; Hess, K.R.; Hossain, A.; Gumin, J.; Gao, F.; Fuller, G.N.; Goodman, L.; Sulman, E.P.; Lang, F.F. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro-oncol., 2017, 19(5), 660-668.
[15]
Grunewald, T.G.; Butt, E. The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Mol. Cancer, 2008, 7, 31.
[16]
Phillips, G.R.; Anderson, T.R.; Florens, L.; Gudas, C.; Magda, G.; Yates, J.R.; Colman, D.R. Actin-binding proteins in a postsynaptic preparation: Lasp-1 is a component of central nervous system synapses and dendritic spines. J. Neurosci. Res., 2004, 78(1), 38-48.
[17]
Ruggieri, V.; Agriesti, F.; Tataranni, T.; Perris, R.; Mangieri, D. Paving the path for invasion: the polyedric role of LASP1 in cancer. Tumour Biol., 2017, 39(6), 1010428317705757.
[18]
Orth, M.F.; Cazes, A.; Butt, E.; Grunewald, T.G. An update on the LIM and SH3 domain protein 1 (LASP1): A versatile structural, signaling, and biomarker protein. Oncotarget, 2015, 6(1), 26-42.
[19]
Dejima, T.; Imada, K.; Takeuchi, A.; Shiota, M.; Leong, J.; Tombe, T.; Tam, K.; Fazli, L.; Naito, S.; Gleave, M.E.; Ong, C.J. Suppression of LIM and SH3 domain protein 1 (LASP1) negatively regulated by androgen receptor delays castration resistant prostate cancer progression. Prostate, 2017, 77(3), 309-320.
[20]
Zhang, X.; Liu, Y.; Fan, C.; Wang, L.; Li, A.; Zhou, H.; Cai, L.; Miao, Y.; Li, Q.; Qiu, X.; Wang, E. Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway. Oncotarget, 2017, 8(43), 75102-75113.
[21]
Wang, H.; Shi, J.; Luo, Y.; Liao, Q.; Niu, Y.; Zhang, F.; Shao, Z.; Ding, Y.; Zhao, L. LIM and SH3 protein 1 induces TGFbeta-mediated epithelial-mesenchymal transition in human colorectal cancer by regulating S100A4 expression. Clin. Cancer Res., 2014, 20(22), 5835-5847.
[22]
Gao, W.; Han, J. Silencing of LIM and SH3 protein 1 (LASP-1) inhibits thyroid cancer cell proliferation and invasion. Oncol. Res., 2017, 25(6), 879-886.
[23]
Traenka, C.; Remke, M.; Korshunov, A.; Bender, S.; Hielscher, T.; Northcott, P.A.; Witt, H.; Ryzhova, M.; Felsberg, J.; Benner, A.; Riester, S.; Scheurlen, W.; Grunewald, T.G.; von Deimling, A.; Kulozik, A.E.; Reifenberger, G.; Taylor, M.D.; Lichter, P.; Butt, E.; Pfister, S.M. Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res., 2010, 70(20), 8003-8014.
[24]
Wu, B.X.; Hong, F.; Zhang, Y.; Ansa-Addo, E.; Li, Z. GRP94/gp96 in cancer: Biology, structure, immunology, and drug development. Adv. Cancer Res., 2016, 129, 165-190.
[25]
Hu, T.; Xie, N.; Qin, C.; Wang, J.; You, Y. Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/beta-catenin signaling pathway. Tumour Biol., 2015, 36(12), 9357-9364.
[26]
Taghipour, M.; Omidvar, A.; Razmkhah, M.; Ghaderi, A.; Mojtahedi, Z. Comparative proteomic analysis of tumor mesenchymal-like stem cells derived from high grade versus low grade gliomas. Cell J., 2017, 19(2), 250-258.
[27]
Tran, D.Q.; Andersson, J.; Wang, R.; Ramsey, H.; Unutmaz, D.; Shevach, E.M. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. USA, 2009, 106(32), 13445-13450.
[28]
Bloch, O.; Crane, C.A.; Fuks, Y.; Kaur, R.; Aghi, M.K.; Berger, M.S.; Butowski, N.A.; Chang, S.M.; Clarke, J.L.; McDermott, M.W.; Prados, M.D.; Sloan, A.E.; Bruce, J.N.; Parsa, A.T. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial. Neuro-oncol., 2014, 16(2), 274-279.
[29]
Tosti, G.; di Pietro, A.; Ferrucci, P.F.; Testori, A. HSPPC-96 vaccine in metastatic melanoma patients: From the state of the art to a possible future. Expert Rev. Vaccines, 2009, 8(11), 1513-1526.
[30]
Biaoxue, R.; Xiguang, C.; Hua, L.; Shuanying, Y. Stathmin-dependent molecular targeting therapy for malignant tumor: The latest 5 years’ discoveries and developments. J. Transl. Med., 2016, 14(1), 279.
[31]
Jeon, T.Y.; Han, M.E.; Lee, Y.W.; Lee, Y.S.; Kim, G.H.; Song, G.A.; Hur, G.Y.; Kim, J.Y.; Kim, H.J.; Yoon, S.; Baek, S.Y.; Kim, B.S.; Kim, J.B.; Oh, S.O. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br. J. Cancer, 2010, 102(4), 710-718.
[32]
Obayashi, S.; Horiguchi, J.; Higuchi, T.; Katayama, A.; Handa, T.; Altan, B.; Bai, T.; Bao, P.; Bao, H.; Yokobori, T.; Nishiyama, M.; Oyama, T.; Kuwano, H. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int. J. Oncol., 2017, 51(3), 781-790.
[33]
Hitosugi, T.; Zhou, L.; Elf, S.; Fan, J.; Kang, H.B.; Seo, J.H.; Shan, C.; Dai, Q.; Zhang, L.; Xie, J.; Gu, T.L.; Jin, P.; Aleckovic, M.; LeRoy, G.; Kang, Y.; Sudderth, J.A.; DeBerardinis, R.J.; Luan, C.H.; Chen, G.Z.; Muller, S.; Shin, D.M.; Owonikoko, T.K.; Lonial, S.; Arellano, M.L.; Khoury, H.J.; Khuri, F.R.; Lee, B.H.; Ye, K.; Boggon, T.J.; Kang, S.; He, C.; Chen, J. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell, 2012, 22(5), 585-600.
[34]
Qu, J.; Sun, W.; Zhong, J.; Lv, H.; Zhu, M.; Xu, J.; Jin, N.; Xie, Z.; Tan, M.; Lin, S.H.; Geng, M.; Ding, J.; Huang, M. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. J. Cell Biol., 2017, 216(2), 409-424.
[35]
Zhang, D.; Jin, N.; Sun, W.; Li, X.; Liu, B.; Xie, Z.; Qu, J.; Xu, J.; Yang, X.; Su, Y.; Tang, S.; Han, H.; Chen, D.; Ding, J.; Tan, M.; Huang, M.; Geng, M. Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity. Oncogene, 2017, 36(20), 2900-2909.
[36]
Fu, B.S.; Liu, W.; Zhang, J.W.; Zhang, T.; Li, H.; Chen, G.H. Serum proteomic analysis on metastasis-associated proteins of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao, 2009, 29(9), 1775-1778.
[37]
Richens, J.L.; Spencer, H.L.; Butler, M.; Cantlay, F.; Vere, K.A.; Bajaj, N.; Morgan, K.; O’Shea, P. Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease. Sci. Rep., 2016, 6, 22962.
Related Journals
Related Books
Industrial Applications of Soil Microbes
Industrial Applications of Soil Microbes
Algal Biotechnology for Fuel Applications
Biopolymers Towards Green and Sustainable Development
Terpenoids: Recent Advances in Extraction, Biochemistry and Biotechnology
Environmental Microbiology: Advanced Research and Multidisciplinary Applications
Biomarkers in Medicine
Industrial Applications of Soil Microbes
Recent Advances in Biotechnology
Sustainable Utilization of Fungi in Agriculture and Industry
Article Metrics
62
3
1
1